Background Injectable luteinizing hormone–releasing hormone agonists (eg, leuprolide) are
the standard agents for achieving androgen deprivation for prostate cancer despite the initial …

Androgen deprivation therapy (ADT) is the primary systemic therapy for treating locally
advanced or metastatic prostate cancer (PCa). Despite its positive effect on PCa patient …

Cancer stem cells (CSCs) and cells in a cancer stem cell-like (CSCL) state have proven to
be responsible for tumor initiation, growth, and relapse in Prostate Cancer (PCa) and other …

Objectives To compare the metabolic changes between men with advanced prostate cancer
commenced on a gonadotropin‐releasing hormone (Gn RH) agonist and those treated with …

Abnormally high follicle-stimulating hormone (FSH) has been reported to associate with
cardiovascular diseases in prostate cancer patients with specific androgen deprivation …

Low testosterone (T), common in aging men, associates with cardiovascular disease. We
investigated whether follicle-stimulating hormone (FSH), which is affected by T, modulates …

Treatment intensification with androgen deprivation therapy (ADT) and androgen receptor
pathway inhibitors (ARPi) have led to improved survival in advanced prostate cancer …

Purpose: Surgical castration for metastatic prostate cancer is used less frequently than
medical castration yet costs less, requires less followup and may be associated with fewer …

Background Androgen deprivation therapy (ADT) is widely being applied in men who
suffered from prostate cancer. Whether androgen deprivation therapy (ADT) is associated …

Abstract Purpose of the Review This review paper is a comprehensive look at the
cardiovascular disease (CVD) risk that is associated with the use of androgen deprivation …